Spontaneous bacterial peritonitis due to Brucella in an HBV-positive cirrhotic patient

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Infection and Chemotherapy Pub Date : 2025-02-26 DOI:10.1016/j.jiac.2025.102663

Yasemin Çakır Kıymaz , Sümeyye Kara Yeşildağ , Sevgi Baltacı , Ayşenur Çömez Baysal , Cihad Baysal , Ertuğrul Keskin , Suna Bozkurt , Mürşit Hasbek , Seyit Ali Büyüktuna , Nazif Elaldı

引用次数: 0

Abstract

Spontaneous bacterial peritonitis (SBP) is a severe complication of cirrhosis, occurring in approximately 15 % of cirrhotic patients. The most common causative pathogens of SBP are Escherichia coli and Klebsiella pneumoniae. Although brucellosis can cause various complications, it is a rare cause of peritonitis. Herein, we report a case of a 30-year-old male with chronic hepatitis B who presented with fever, night sweats, weight loss, abdominal pain, and distension. Brucella spp. was isolated from blood and peritoneal fluid cultures. The patient fully recovered following six weeks of treatment with oral doxycycline (100 mg twice daily) and rifampicin (600 mg/day). No relapses or complications were observed during follow-up.

查看原文本刊更多论文

乙肝病毒阳性肝硬化患者布鲁氏菌所致自发性细菌性腹膜炎。

自发性细菌性腹膜炎（SBP）是肝硬化的严重并发症，约占肝硬化患者的15%。SBP最常见的致病菌是大肠杆菌和肺炎克雷伯菌。虽然布鲁氏菌病可引起各种并发症，但它是腹膜炎的罕见病因。在此，我们报告一例30岁男性慢性乙型肝炎患者，其表现为发烧、盗汗、体重减轻、腹痛和腹胀。从血液和腹膜液培养中分离出布鲁氏菌。患者在口服强力霉素（100mg，每日两次）和利福平（900mg /天）治疗六周后完全康复。随访期间无复发及并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY

CiteScore

4.10

自引率

4.50%

发文量

303

审稿时长

47 days

期刊介绍： The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.